Table 1.
Study Population Features. Descriptive statistics of sample features. ITP—Immune Thrombocytopenic Purpura. TPO-RA—TPO Receptor Agonist. SD—standard deviation.
| Study Population Features | N = 64 |
|---|---|
| Age (years), mean (SD) | 62.39 (17.26) |
| Gender, n (%) | |
| Male | 23 (35.90) |
| Female | 41 (64.10) |
| Number of previous ITP treatments, median | 2 |
| Previous splenectomy (%) | 15 (23.40) |
| On therapy at infection/vaccination time, n (%) | 44 (68.75) |
| Steroids | 1 (1.56) |
| Steroids and TPO-RA | 3 (4.68) |
| TPO-RA | 37 (57.81) |
| Azathioprine | 2 (3.12) |
| Azathioprine and TPO-RA | 1 (1.56) |
| Off Therapy at infection/vaccination time, n (%) | 20 (31.25) |
| First Dose Anti-SARS-CoV-2 Vaccination, n (%) | 61 |
| Comirnaty, Pfizer Biontech | 52(85.24) |
| Spikevax, Moderna | 8 (13.10) |
| Vaxzevria, Astrazeneca | 1 (1.64) |
| Second Dose Anti-SARS-CoV-2 Vaccination, n (%) | 58 |
| Comirnaty, Pfizer Biontech | 50 (86.20) |
| Spikevax, Moderna | 8 (13.79) |
| Third Dose Anti-SARS-CoV-2 Vaccination, n (%) | 34 |
| Comirnaty, Pfizer Biontech | 27 (79.41) |
| Spikevax, Moderna | 7 (20.58) |